3M Company (NYSE:MMM) gained 1.4% on September 26, after Bernstein upgraded the stock from Underperform to Market Perform and raised its price target from $145 to $171. Analyst Varun Govindaraj pointed to a refreshed understanding of the company’s transformation after a recent meeting with management.
The thesis now includes an R&D “factory” model, a short-cycle recovery fueled by AI capital spending, and lower PFAS legal risk. Still, Bernstein stopped at Market Perform, suggesting that even its newly converted analyst sees the stock as roughly fully valued after its recent run. In other words, the note is more constructive on the transformation than it is on the stock’s remaining upside.
3M’s turnaround may be ahead of schedule, but PFAS risks haven’t disappeared. See what’s still hanging over the stock here.
What Was Behind the Upgrade?
Analyst Varun Govindaraj said 3M Company’s “R&D factory” approach has structurally changed the company by treating product commercialization as a portfolio, with regular pipeline reviews and a focus on returns. He believes previous headwinds, including PFAS replacement work and healthcare’s capital drain, are no longer weighing on results. As a result, he raised his organic growth forecast to 3.5% to 4% from roughly 3%. Varun Govindaraj sees 3M entering the early stages of a short-cycle recovery, likely driven by AI spending. His PFAS outlook has become less cautious because the company is negotiating personal injury settlements directly rather than dealing with bellwether trials. He is also comfortable with operating margins of about 25% this year.
The Litigation Overhang Is Paused, Not Resolved
3M still faces more than 15,000 personal injury cases, with the October 2025 kidney-cancer bellwether trial vacated and no replacement date set as of August. Without a verdict or settlement, there is still no clear valuation anchor. The fact that negotiations are ongoing does not establish an outcome. At the same time, much of the operational turnaround is already reflected in the stock. Second-quarter adjusted organic growth reached 5.4%, and the company had already raised its earnings guidance before Bernstein’s note. Even the new $171 target suggests limited upside from the current levels. Consumer electronics remains in decline, while GAAP operating margin fell to 15.1%.
3M’s Turnaround Is Already in the Price
3M’s valuation backs up Bernstein’s decision to stop at Market Perform. The forward GAAP P/E of 21.92x has no meaningful 5-year average, since large legal charges in past years distort its earnings history. The forward Price-to-sales ratio of 3.33x, though, sits about 27% above its 5-year average of 2.62x. That’s a sizable premium for the growth on offer. Analysts expect earnings to rise about 11% this year, then slow steadily to around 6% by 2029. 3M also carries $13.16 billion in debt against $5.30 billion in cash, before accounting for any future PFAS settlements. To me, the turnaround is real, but investors are already paying for it while the legal risk remains open.
3M saw stronger institutional interest during the quarter, with the number of hedge funds holding the stock rising from 63 funds at the end of Q1 2026 to 72 funds at the end of Q2 2026. Short interest was still relatively low at 1.79% of float as of August 31, 2026.
The R&D factory approach and short-cycle recovery thesis are supported by two years of beat-and-raise results, and investor positioning reinforces that narrative. More hedge funds are holding the stock, while short interest remains below 2%. Still, Bernstein’s own Market Perform rating limits the enthusiasm around the upgrade. Those buying into the institutional buildup are still taking on PFAS uncertainty, with no court having yet established a valuation outcome.
READ NEXT: SpaceX’s Falcon 9 Wind Down: Rocket Lab Is Set To Gain, Here’s How And Vicor (VICR) Stock Is Rallying on Royalties. History Says Be Careful
Hedge Fund Resource Center